Sanofi-aventis

Related Articles

Clinical Trial/Study

Non-Adherence to Antiplatelet Therapy Following PCI Results in More Ischemic, Bleeding Events
Study Shows Drug Lowers LDL in Hypercholesterolemia Patients
Study Shows Otamixaban Intravenous Anti-Coagulant Reduces PCI Complications
Study: Afib Patients Can Reduce Stroke Risk by Taking Plavix Plus Aspirin
Antiarrhythmic Drug Shows Significant Reduction in Hospitalization, Death in Study

Cath Lab

Non-Adherence to Antiplatelet Therapy Following PCI Results in More Ischemic, Bleeding Events

Antiplatelet Therapy

Non-Adherence to Antiplatelet Therapy Following PCI Results in More Ischemic, Bleeding Events

Cardiovascular Surgery

Non-Adherence to Antiplatelet Therapy Following PCI Results in More Ischemic, Bleeding Events

EP Lab

Barry Manilow Urges Americans to Learn About Health Risks of AFib
Atrial Fibrillation Drug Receives European Approval
Get Back in Rhythm

Pharmaceuticals

Study Shows Drug Lowers LDL in Hypercholesterolemia Patients
Atrial Fibrillation Drug Receives European Approval
Dronedarone Helps Reduce Stroke in AF Patients According to New Study
Multaq (dronedarone) Recommended for European Approval
Study Shows Otamixaban Intravenous Anti-Coagulant Reduces PCI Complications
MULTAQ for Atrial Fibrillation, Atrial Flutter Now Available
FDA Approves New Drug to Treat Atrial Fibrillation, Atrial Flutter
Study: Afib Patients Can Reduce Stroke Risk by Taking Plavix Plus Aspirin
FDA Advisory Committee Recommends Approval of Multaq for AF
Antiarrhythmic Drug Shows Significant Reduction in Hospitalization, Death in Study
Lovenox Approved for Acute STEMI Patients

Cardiac Rhythm Management Therapy

New Analysis Illustrates the Hidden Burden of Atrial Fibrillation on Healthcare Spending and Resources in Each State
Dronedarone Helps Reduce Stroke in AF Patients According to New Study
Multaq (dronedarone) Recommended for European Approval
FDA Approves New Drug to Treat Atrial Fibrillation, Atrial Flutter
FDA Advisory Committee Recommends Approval of Multaq for AF
Antiarrhythmic Drug Shows Significant Reduction in Hospitalization, Death in Study

General Cardiology

FDA Advisory Committee Recommends Approval of Multaq for AF